Literature DB >> 22159384

The burden of ischemic heart disease at a major cardiac center in Central Saudi Arabia.

Ahmed M Osman1, Mohammed S Alsultan, Meshal A Al-Mutairi.   

Abstract

OBJECTIVE: To estimate the direct medical costs associated with ischemic heart disease (IHD) at Prince Sultan Cardiac Center (PSCC) in Riyadh, Saudi Arabia.
METHODS: This is a prevalence-based prospective observational cost of illness study conducted in PSCC, Riyadh, Kingdom of Saudi Arabia between April and June 2009. All patients diagnosed or suspected of having IHD at admission were included. They were followed up until discharge, or performing coronary artery bypass graft (CABG), or changing diagnosis. Clinical data were extracted from the patients' computerized database, and combined with the unit cost of services to calculate costs.
RESULTS: A total of 205 patients were recruited and diagnosed with stable angina (SA, 47.8%), unstable angina (USA, 24.4%), ST-segment elevation myocardial infarction (STEMI, 19.5%), and non-ST-segment elevation myocardial infarction (NSTEMI, 8.3%). Most of the patients were Saudi males, aged between 40-75 years. Eighty-seven percent of patients had 2 or more co-morbidities, and 32% of the patients were obese. The average cost was 40,164 Saudi Riyals (SAR)/patient (US$10,710). Medication contributed the lowest in the costs (3.2%). A cost associated with SA was SAR33,991, USA was SAR35,107, NSTEMI was SAR46,585, and STEMI was SAR58,877 per patient. The lowest mean hospital length of stay was 6.5 days with SA. The average length of stay increased with the number of co-morbidities from 5.67 days (no co-morbidity) to 11.25 days (6 co-morbidities).
CONCLUSION: The IHD is of high economic burden in the country. Among IHD types studied, the resource consumption associated to STEMI was the highest in terms of costs, and hospital length of stay.

Entities:  

Mesh:

Year:  2011        PMID: 22159384

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  6 in total

Review 1.  Costs associated with management of non-communicable diseases in the Arab Region: a scoping review.

Authors:  Shadi Saleh; Amena El Harakeh; Maysa Baroud; Najah Zeineddine; Angie Farah; Abla Mehio Sibai
Journal:  J Glob Health       Date:  2018-12       Impact factor: 4.413

Review 2.  The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region.

Authors:  Kevin Cheng; Khaldoon Alhumood; Fayez El Shaer; Ranil De Silva
Journal:  Adv Ther       Date:  2020-12-22       Impact factor: 3.845

3.  Prevalence of coronary artery disease and its risk factors in Majmaah City, Kingdom of Saudi Arabia.

Authors:  Haitham M Albar; Riyadh Ahmed Alahmdi; Abdulmalik A Almedimigh; Riyaz Ahmed Shaik; Mohammad Shakil Ahmad; Abdulaziz Badar Almutairi; Waleed Khalid Z Alghuyaythat; Shouq Yaseen Alaoufi; Worud Omar Aloyari; Rand Muslat S Alanazi
Journal:  Front Cardiovasc Med       Date:  2022-09-08

4.  Cost-Effectiveness of More Intensive Blood Pressure Treatment in Patients with High Risk of Cardiovascular Disease in Saudi Arabia: A Modelling Study of Meta-Analysis.

Authors:  Ziyad Almalki; Yasser Alatawi; Adnan Alharbi; Bader Almaklefi; Suliman Alfaiz; Omar Almohana; Yasser Alsaidan; Abdullah Alanezi
Journal:  Int J Hypertens       Date:  2019-09-30       Impact factor: 2.420

5.  Adherence to prophylactic dual antiplatelet therapy in patients with acute coronary syndrome - A study conducted at a Saudi university hospital.

Authors:  Ziyad Alrabiah; Syed Wajid; Ibrahim Alsulaihim; Sultan Alghadeer; Abdulaziz Alhossan; Salmeen D Babelghaith; Mohamed Al-Arifi
Journal:  Saudi Pharm J       Date:  2020-02-03       Impact factor: 4.330

6.  Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia.

Authors:  Ahmed Alghamdi; Bander Balkhi; Abdulaziz Altowaijri; Nasser Al-Shehri; Lewis Ralph; Emily-Ruth Marriott; Michael Urbich; Fawaz Aljanad; Rima Aziziyeh
Journal:  Pharmacoecon Open       Date:  2021-09-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.